Skip to main content
. 2023 Sep 7;9(9):e19951. doi: 10.1016/j.heliyon.2023.e19951

Fig. 3.

Fig. 3

Targeting figure of IL-1β inhibitors in the treatment of IDD. IL-1RAcP, IL-1 receptor accessory protein; IL-1RI, IL-1 receptor type I; IL-1β, interleukin-1β; MyD88, myeloid differentiation factor 88; NF-κB, nuclear factor kappa-B; MAPK, mitogen-activated protein kinase, NLRP3, NOD-like receptor thermal protein domain associated protein 3.